
This study investigated the role of CD276 in advanced prostate cancer (PCa) and its potential as a target for immunotherapy. CD276 was identified as a key molecule regulating the immune microenvironment (IM) through transcriptomic and proteomic analyses. In vivo and in vitro experiments confirmed that CD276 knockdown enhanced CD8+ T cell infiltration into the IM. Immunohistochemical analysis of PCa samples supported these findings. The study concluded that CD276 inhibits the enrichment of CD8+ T cells in PCa, suggesting that CD276 inhibitors could serve as potential targets for immunotherapy in advanced PCa.
Like
Save
Share